Finland’s FIMEA Issues Guidance on EU AI Act Requirements for AI Enabled Medical Devices Effective January 19, 2026

Details of the Update

The guidance explains that medical devices incorporating artificial intelligence (MDAI) are now regulated under a combined framework of MDR, IVDR, and the EU AI Regulation, rather than under medical device legislation alone. It emphasizes the need to ensure safety, ethical sustainability, and transparency across the entire lifecycle of AI-enabled medical devices.

Companies placing AI enabled devices on the EU market are required to address expanded quality management obligations, including strengthened lifecycle risk assessment, more robust technical documentation, and clearer transparency measures related to AI functionality. The guidance also highlights the importance of data handling and data governance practices, reflecting AI specific risks such as data quality, bias, and system performance over time.

For high-risk AI systems, the guidance signals the application of stricter regulatory controls, particularly around safety, transparency, and oversight. Implementation of these requirements will take place in phases, with further clarification expected as EU level discussions continue, and national legislation is finalized. As a result, specific timelines may evolve.

Effective Date

This guidance provides regulatory clarity on how the EU AI Regulation interacts with existing medical device frameworks, supporting more consistent interpretation across compliance functions. It reinforces digital alignment by integrating AI specific risk management and data governance into established medical device processes, while aiming to improve efficiency through clearer expectations. At the same time, the phased approach is intended to minimize unnecessary regulatory burden as requirements are progressively defined.

Why This Is Relevant For

This update is particularly relevant for Regulatory Affairs, Quality Assurance, R&D, IT, and AI development teams involved in the design, compliance, and lifecycle management of AI enabled medical devices intended for the EU market.

Who This Is Relevant For

This development is relevant for Regulatory Affairs, Quality Assurance, Legal and Compliance, R&D, patient safety groups, and commercial or marketing teams involved in food product oversight, nutrition research, and food safety monitoring across the U.S. market.

Next Steps

Organizations should evaluate current product portfolios to identify AI components and assess alignment with both MDR IVDR and AI specific requirements. Internal processes for lifecycle risk management, data handling, and technical documentation should be reviewed and updated where necessary. Stakeholders should also monitor Fimea’s website for further instructions on phased implementation and be prepared to adapt quality systems as additional guidance is published.

As AI regulations increasingly intersect with medical device compliance, staying ahead of evolving requirements becomes critical. RegASK is a leading agentic AI regulatory intelligence and workflow orchestration platform that empowers global organizations in highly regulated sectors, including life sciences, to proactively navigate complex regulatory landscapes. By combining advanced Agentic AI with experts in the loop, RegASK delivers timely predictive actionable insights and end to end automation, helping teams track AI related regulatory updates, assess impact, and streamline compliance across more than 140 countries. Learn more or book a demo now. 

FAQs

What does FIMEA’s guidance focus on?

It clarifies how AI enabled medical devices are regulated under the EU AI Regulation in combination with MDR and IVDR requirements.

Which regulations apply to AI-enabled medical devices in the EU?

AI enabled medical devices must comply with MDR or IVDR as well as the EU Artificial Intelligence Regulation.

When does the guidance take effect?

The guidance was published on January 19, 2026, with phased implementation anticipated as EU and national requirements are finalized.

How can RegASK support teams affected by this update?

RegASK helps regulatory and compliance teams monitor AI related regulatory changes, assess their impact on medical device portfolios, and operationalize compliance actions efficiently through AI driven insights and expert validated workflows.